Umberto Pensato, Federica Pondrelli, Chiara de Philippis, Gian Maria Asioli, Alessandra Crespi, Alessandro Buizza, Daniele Mannina, Beatrice Casadei, Enrico Maffini, Laura Straffi, Simona Marcheselli, Pier Luigi Zinzani, Francesca Bonifazi, Maria Guarino, Stefania Bramanti
INTRODUCTION: Seizures may occur in up to 30% of non-Hodgkin lymphoma patients who received anti-CD19 CAR T-cell therapy, yet the optimal anti-seizure medication (ASM) prevention strategy has not been thoroughly investigated. METHODS: Consecutive patients affected by refractory non-Hodgkin lymphoma who received anti-CD19 CAR T-cells were included. Patients were selected and assessed using similar internal protocols. ASM was started either as a primary prophylaxis (PP-group) before CAR T-cells infusion or as a pre-emptive therapy (PET-group) only upon the onset of neurotoxicity development...
March 21, 2024: Neurological Sciences